

## ICMJE DISCLOSURE FORM

Date: 14 December 2022

Your Name: Woo-Jung Song

Manuscript Title: Cough Focused Series: Progress in understanding and management of chronic cough

Manuscript number (if known): JTD-22-1743

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   |  | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|--|---|
| <b>Time frame: Since the initial planning of the work</b> |  |  |   |
| 1   | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)<br><b>No time limit for this item.</b> | None   |   |
|   |  |  |   |
|   |  |  |   |
|   |  |  |   |
|   |  |  |   |
|   |  |  |   |
| <b>Time frame: past 36 months</b>                         |  |  |   |
| 2   | Grants or contracts from any entity (if not indicated in item #1 above).   | MSD  | To myself   |
| 3   | Royalties or licenses  | None   |   |
| 4   | Consulting fees  | MSD, AstraZeneca, Shionogi, and GSK  | To myself   |

|    |  |   |           |
|----|--|---|-----------|
|    |  |   |           |
| 5  | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | <u>  </u> MSD, GSK, AstraZeneca, and Novartis | To myself |
| 6  | Payment for expert testimony   | <u>  </u> None                                |           |
| 7  | Support for attending meetings and/or travel   | <u>  </u> None                                |           |
| 8  | Patents planned, issued or pending   | <u>  </u> None                                |           |
| 9  | Participation on a Data Safety Monitoring Board or Advisory Board  | <u>  </u> None                                |           |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid            | <u>  </u> None                                |           |
| 11 | Stock or stock options   | <u>  </u> None                                |           |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services                             | <u>  </u> None                                |           |
| 13 | Other financial or non-financial interests   | <u>  </u> None                                |           |

**Please summarize the above conflict of interest in the following box:**

WJS declares academic grants from MSD, consulting fees from MSD, GSK, AstraZeneca, and Novartis, and honoraria from MSD, GSK, AstraZeneca, and Novartis.

**Please place an "X" next to the following statement to indicate your agreement:**

  X   I certify that I have answered every question and have not altered the wording of any of the questions on this form.

## ICMJE DISCLOSURE FORM

Date: 13\_12\_2022

Your Name: Kian Fan CHUNG

Manuscript Title: Cough Focused Series: Progress in understanding and management of chronic cough

Manuscript number (if known): JTD-22-1743

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   |  | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|--|---|
| <b>Time frame: Since the initial planning of the work</b> |  |  |   |
| 1   | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)<br><b>No time limit for this item.</b> | _____ None   |   |
|   |  |  |   |
|   |  |  |   |
|   |  |  |   |
|   |  |  |   |
|   |  |  |   |
|   |  |  |   |
| <b>Time frame: past 36 months</b>                         |  |  |   |
| 2   | Grants or contracts from any entity (if not indicated in item #1 above).   | MRC grant on Precision Medicine for severe asthma  | To my Institution   |
|   |  | EPSRC grant on air pollution and asthma  | To my institution   |

|    |  |  |                         |
|----|--|--|-------------------------|
|    |  | GSK grant on mepolizumab and eosinophils in asthma   | To my institution       |
| 3  | Royalties or licenses  | _____ None   |                         |
|    |  |  |                         |
|    |  |  |                         |
| 4  | Consulting fees  | _____ None   |                         |
|    |  |  |                         |
|    |  |  |                         |
| 5  | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | Speaking engagements for Novartis, AZ and Merck  | To myself               |
|    |  |  |                         |
|    |  |  |                         |
| 6  | Payment for expert testimony   | _____ None   |                         |
|    |  |  |                         |
|    |  |  |                         |
| 7  | Support for attending meetings and/or travel   | _____ None   |                         |
|    |  |  |                         |
|    |  |  |                         |
| 8  | Patents planned, issued or pending   | _____ None   |                         |
|    |  |  |                         |
|    |  |  |                         |
| 9  | Participation on a Data Safety Monitoring Board or Advisory Board  | Advisory Board meeting for GSK, Astra Zeneca, Novartis, Roche, Merck, Rickett- Beckinson, Nocion & Shionogi on asthma, COPD and chronic cough. Scientific Advisory Board of the Clean Breathing Institute supported by Haleon. | Payments made to myself |
|    |  |  |                         |
|    |  |  |                         |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid            | _____ None   |                         |
|    |  |  |                         |
|    |  |  |                         |
| 11 | Stock or stock options   | _____ None   |                         |
|    |  |  |                         |
|    |  |  |                         |

|    |  |  |                                  |
|----|--|--|----------------------------------|
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ____ None  |                                  |
|    |  |  |                                  |
| 13 | Other financial or non-financial interests                                       | Educational support for the 12 <sup>th</sup> London International Cough Symposium in July 2022 from Merck. | Payments made to my Institution. |
|    |  |  |                                  |

Please place an "X" next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on this form.